

# ZBTB28 induce autophagy via regulating FIP200 and Bcl-XL to facilitate apoptosis of cervical cancer

**Li Li**

Chongqing Medical University

**YiJia Gong**

Chongqing Medical University

**Ke Xu**

Chongqing Medical University

**WeiHong Chen**

Chongqing Medical University

**JiuYi Xia**

Chongqing Medical University

**ZhaoBo Cheng**

Chongqing Medical University

**Lili Li**

Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences

**RenJie Yu**

Chongqing Medical University

**JunHao Mu**

Chongqing Medical University

**Xin Le**

Chongqing Medical University

**Qin Xiang**

Chongqing Medical University

**WeiYan Peng**

Chongqing Medical University

**JunYing Tang**

Chongqing Medical University

**Tingxiu Xiang** (✉ [Xiangtx@cqmu.edu.cn](mailto:Xiangtx@cqmu.edu.cn))

Chongqing Key Laboratory of Molecular Oncology and Epigenetics, the First Affiliated Hospital of Chongqing Medical University

**Keywords:** ZBTB28, Cervical cancer, autophagy, apoptosis, BECN1, FIP200

**Posted Date:** February 12th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-214115/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Background

Cervical cancer is a type of cancer with the highest morbidity among the common preventable cancers in women. It is curable if detected in early stage. This kind of carcinoma is in need of reliable diagnostic and prognostic markers that involved in the regulation of its physiologic and pathological processes. However, the functions and mechanism of ZBTB28 in cervical cancer remain unclear.

## Methods

Public database analysis, reverse-transcription PCR, and methylation-specific PCR were employed to analyze ZBTB28 expression and methylation. Tumor cellular functions were assessed via corresponding cellular and molecular biological approaches in vitro and in vivo.

## Results

Our study contributed to the anti-tumor effect of transcription factor ZBTB28 which is often silenced in cervical cancer due to promoter CpG methylation. Via molecular and cellular approaches, we found that ectopic expression of *ZBTB28* directly affected the biological function of cervical cancer including cell proliferation, apoptosis, autophagy and tumorigenesis, as well as chemosensitivity to Paclitaxel, Cisplatin and 5-FU. Ectopic ZBTB28 expression inhibited the growth of cervical cancer xenografts in nude mice. Furthermore, the electron microscopic photograph showed that ZBTB28 could induce the autophagosome in cervical cancer cells. ZBTB28 resulted in autophagy through degradation of *Bcl-XL* and reduction of the Bcl-XL–BECN1 complex, but also interacted with autophagy-related gene *FIP200*. It is worth noticing that ZBTB28-induced autophagy of cervical cancer to mediate cell apoptosis through the regulation of FIP200.

## Conclusion

Our findings enriched the functional diversity of ZBTB28 as a tumor suppressor gene, also illustrated that ZBTB28 could lead to autophagy-related apoptosis in cervical cancer, implying that ZBTB28 may be a target for the treatment of carcinoma of uterine cervix, and detection of ZBTB28 methylation can offer a new objective strategy for screening of cervical cancer.

## Background

Cervical cancer ranks the fourth in the global incidence of female tumors. Despite the continuous improvement of traditional treatment methods, it still causes more than 300,000 deaths worldwide every year [1]. It is well known that the development of cervical cancer is a multi-step carcinogenic process, which is a comprehensive result of the activation of multiple oncogenes and the inactivation of tumor suppressor genes [2]. Many cases of cervical cancer are diagnosed at advanced and incurable stages,

and traditional medicine and surgical treatment are not satisfactory [3]. In order to improve the outcomes of cervical cancer, identification of effective early prognostic biomarkers is urgent.

ZBTB28 (also known as BCL6B, ZNF62 or BAZF) is a recently discovered tumor suppressor gene [4], which belonged to the POK/ZBTB family and was originally discovered by cloning the BCL6 homologous gene [5]. It has been found in a variety of human tumors, it is down-regulated by promoter methylation and shows an anti-cancer function through inhibiting the proliferation viability, invasion and migration ability, and promoting the apoptosis [6, 7]. Remarkably, in our study, we showed for the first time that overexpression of ZBTB28 could induce cervical cancer cells CaSki and HeLa to produce autophagosomes by transmission electron microscope.

Macroautophagy (hereafter autophagy) is an evolutionarily conserved cellular catabolic process that delivers intracellular components such as cytoplasmic macromolecules and organelles to lysosomes for degradation [8, 9]. It plays an important role in human diseases such as cancer, infections and neurodegenerative disorders. Besides, it is also involved in various other physiological pathways, including the cell apoptosis process [10-12]. The process of canonical autophagy is regulated by autophagy-related genes such as BECN1, ATG5 and ATG7 which play a key role at different stages of autophagy [13, 14]. In recent years, alternative autophagy independent of BECN1/ATG5/ATG7 has been discovered [15, 16]. For example, FIP200 was showed having crucial function in regulation of autophagy in mammalian cells via FIP200-ULK1/2-ATG13-ATG101 complex which can initiate both the canonical and the alternative pathway of autophagy [17]. Numerous studies have indicated that autophagy might be a double-edged sword in the process of tumor development. However, how autophagy acts as both a protector and executioner of cell death in cancer still remains controversial. Although autophagy can increase the tolerance of tumor cells to stressors and protect cancer cell survival in unfavorable environments, it is probably noteworthy that autophagy can inhibit the occurrence and metastasis of tumors, and promote tumor cell death through complementing the apoptosis pathway [18, 19]. The anti-apoptotic proteins such as Bcl2 and Bcl-XL have been proved to inhibit autophagy by interacting with BECN1, an autophagy-inducing protein containing a BH3 domain [20]. This suggests that it may be necessary to define the function of autophagy in tumor development in a context-specific manner. An increasing number of studies have indicated that the signaling pathways of autophagy and apoptosis are inextricably linked and synergistic while they are significantly different in morphology and metabolic pathways [21-24]. For instance, autophagy and apoptosis were supplementary to each other to suppress gastric cancer [21], breast cancer [25], leukemia [23] and other tumors. However, whether ZBTB28 can induce autophagy and apoptosis to play an anti-cancer role in cervical cancer remains elusive.

In our study, we characterized the roles of ZBTB28 in carrying out tumor suppressive functions that were relevant to occurrence of cervical cancer. We demonstrated that re-expression of ZBTB28 inhibited cervical cancer cell growth and motility, as well as promoted autophagy-related apoptosis. In vivo experiment, ZBTB28 led to a decrease in cervical carcinoma xenograft growth and inhibited experimental lung metastasis. Moreover, we showed that ZBTB28 increased the sensitivity of cells toward anticancer drugs such as Paclitaxel, Cisplatin and 5-fluorouracil (5-FU). In addition, the further mechanism studies

showed that stimulated of FIP200 and dampened of Bcl-XL expression are crucial for ZBTB28-induced autophagy and apoptosis. All the results identified that ZBTB28 played a crucial role in regulation of various biological functions in cervical cancer cell lines, and it may be a potential candidate diagnostic and therapeutic target for cervical cancer patients.

## Materials And Methods

### Cell lines, tumor samples and normal tissues

Cell lines (Hela, CaSki, HEK293T) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and collaborators. Cancer cell lines (Hela, CaSki) were cultured in RPMI 1640 medium (Gibco-BRL, Karlsruhe, Germany) with 10% fetal bovine serum (FBS), and 293T cells were grown in high glucose DMEM (Gibco-BRL, Karlsruhe, Germany) supplemented with 10% FBS. All cells were cultured at 37 °C in a humidified atmosphere containing 5% CO<sub>2</sub>.

All tissue samples used were acquired from the First Affiliated Hospital of Chongqing Medical University, including primary tumor and paired surgical margin tissues as well as normal tissues. In order to make sure that the percentage of tumor cells was over 70%, tissue samples were pathologically and histologically examined with collection of clinical and pathological data followed. This study was conducted according to provisions of the Helsinki Declaration in 1975 and authorized by the Institutional Ethics Committees of the First Affiliated Hospital of Chongqing Medical University (Approval notice: No.20180305).

### Construction of plasmids and transfection

To construct the *ZBTB28* expression plasmid, the homo sapiens *ZBTB28* full-length gene with a HA-tag was cloned into the pcDNA-3.1(+) framework plasmid. The recombinant plasmids were transformed into *E.coli* DH5a cells (CB101, TIANGEN) and then sequenced. Cells were transfected with plasmid DNA using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Stably transfected pcDNA-3.1 and pcDNA-ZBTB28 cells were acquired by G418 selection (600 µg/ml for CaSki, 800 µg/ml for HeLa).

### RNA isolation, Reverse transcriptase-PCR and Real-Time PCR

Learning from the manufacturer's instructions, total RNA was isolated from cell lines and clinical samples using TRIzol Reagent® (Molecular Research Center, Cincinnati, OH, USA). 20 µl cDNA was synthesized from 1 µg RNA by Reverse transcriptase-polymerase chain reaction (RT-PCR). Real-time PCR was performed by using Go-Taq (Promega, Madison, WI, USA) under the following conditions: initial denaturation at 95 °C for 2 min, followed by 32 cycles (95 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s) of amplification, and final extension at 72 °C for 3 min. β-actin was amplified as a control and with 23 cycles. Semi-quantitative RT-PCR, with β-actin as a control, was put into practicing with Go-Taq DNA polymerase (Promega) and performed by using a final volume of 10µL reaction mixture that contained 2

μL cDNA. The amplified products were electrophoretic in 2% agarose gel to detect the target bands. In the case of SYBR Green (Thermo Fisher), Real-time quantitative PCR had performed. With the action of 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), all analyses were performed. The primer sequences are shown in Table.S2 and Table.S3.

### **5-Aza-2'-deoxycytidine (5-Aza) treatment**

CaSki and Hela cell lines were treated with 10 μmol/L 5-Aza (Sigma-Aldrich, Steinheim, Germany), a demethylation agent, for 4 days. Then cells were harvested for qRT-PCR analysis.

### **Bisulfite treatment, methylation-specific PCR (MSP) and quantitative methylation specific PCR (qMSP)**

To evaluate *ZBTB28* methylation status, bisulfite modification of DNA was performed [26]. By using AmpliTaq-Gold DNA Polymerase (Applied Biosystems), MSP was then exercised with methylation-specific primers to specifically recognize unmethylated or methylated *ZBTB28* gene sequences. Products were electrophoresis with 2% agarose gels (MBI Fermentas, Vilnius, Lithuania) and recorded on a gel imaging system (Bio-RAD Gel Doc XR+, CA). The primers of qMSP were mentioned before [7].

### **Tumor xenograft model and metastasis models in nude mice**

All animal experiments in this study were conducted in compliance with animal protocols approved by the Experimental Animal Center of Chongqing Medical University, and were approved by the institutional ethics committee of the First Affiliated Hospital of Chongqing Medical University, China. Six BALB/c nude mice (aged 4–6 weeks, weighing 18–22 g) were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd. Stable *ZBTB28*- expression Hela cells or control cells ( $5 \times 10^6$  cells were resuspended in 100 ul PBS) were injected into subcutaneous tissues on both sides of the back of 6 nude mice. The primary tumor size was measured on the fourth day after injection. The second measurement was performed on the eighth day. And then measurements had been taken every two days until the 18th day after injection. The longest and the shortest diameters of tumors were measured using vernier calipers, and tumors' volume ( $\text{mm}^3$ ) were calculated as follows: volume = length  $\times$  width<sup>2</sup>  $\times$  0.52. All nude mice were euthanized the 19th day after injection, and their tumors were collected and weight. Some of the collected tumor tissues were used for embedding sections, and some were frozen in -80 °C refrigerator for subsequent experiments. As previously described [27], female BALB/c nude mice (5–6 weeks) were used in metastasis assays. Two weeks after tail vein injection, the mice were sacrificed and checked for lung metastasis using standard histological examination (Approval notice: No.20180226).

### **Flow cytometry (FCM)**

Cell cycle arrest and apoptosis were assayed by flow cytometry (FCM). For cell cycle analysis, stably transfected cells were harvested with trypsin, then washed twice with PBS, suspended with ice-cold 75% ethanol and fixed overnight. The next day, cells added with RNA enzyme were incubated at 37 °C for 30 min, and stained with propidium iodide (PI) for 30 min in dark to assay for cell cycle distribution. In order

to analyze apoptosis, transiently transfected cells were double staining with annexin V-fluorescein isothiocyanate and PI. A Cell Quest kit (BD Biosciences, CA, USA) was employed to assess FCM results.

### **Cell proliferation (CCK8)**

CaSki and Hela cells were cultured in 96-well plates at a density of 3000 cells/well after transfection with *ZBTB28*-expressing or control (pcDNA3.1) plasmids. The absorbance of cells in each well at 450 nm was measured with CCK8 kit at 0 h, 24 h, 48 h, 72 h, and the mean value of each well was obtained after testing nine times.

For the half maximal inhibitory concentration (IC<sub>50</sub>) determination, cells were treated with progressively increased concentrations of drugs for 72 h. Cisplatin (HY-17394), Paclitaxel (HY-B0015) and 5-FU (HY-90006) were purchased from MedChemExpress. The value of IC<sub>50</sub> was calculated by nonlinear regression analysis with software program GraphPad Prism version 5.

### **Colony formation assays**

Stably transfected pcDNA-3.1 and pcDNA-ZBTB28 cells (CaSki and Hela) were plated in six-well plates (200 cells/well). After 12 day, cells were fixed with 4% Paraformaldehyde (PFA) for 30 min and stained with gentian violet (Beyotime Institute of Biotechnology, Shanghai, China). Photographed with a phase contrast microscope (Leica DMI4000B, Milton Keynes, Buckinghamshire, UK), colonies with more than 50 cells were manually counted with Photoshop software.

### **Transwell® assays for cell migration and invasion**

For Transwell® assays, the chambers (8 µm pore size, BD Sciences, Bedford, MA) with or without Matrigel (100 µg/ml, BD Biosciences, San Jose, CA) were used to get assessment to cell migration and invasion capacities. For migration assay, collected cells were washed twice in serum-free medium and added to the upper compartment ( $3 \times 10^4$  cells). The lower chamber contained 700 µl RPMI 1640 medium containing 20% fetal bovine serum (FBS). For invasion assay, the matrix gel was precoated on the upper compartment. After incubation for 48 h, cells were fixed with 4% paraformaldehyde for 30 min and stained for 30 min with crystal violet. Non-migratory cells on the upper side of the chamber were wiped away gently. Photographed with a phase-contrast microscope (Leica DMI4000B) after fixation and staining, migrated cells were counted. five fields of view were randomly selected for counting.

### **Immunofluorescence and Western Blot**

Immunofluorescence was performed as previously described [28]. Cells grown on round coverslips were incubated with HA-tag (#3724, Cell Signaling Technology), anti-Vimentin (sc-6260, Santa Cruz), and anti-E-cadherin (#14472, Cell Signaling Technology) antibodies and secondary antibodies conjugated with Alexa Fluor 488 and 594. Nuclei were counterstained with DAPI (C1006, Beyotime Biotechnology, Haimen, China). Images were acquired on a fluorescence microscope (Olympus, Tokyo, Japan) using 40 × objective.

Western blot was performed to determine the levels of the autophagic proteins p62 (#8025, Cell Signaling Technology), LC3 (ab128025, abcam), apoptosis proteins Cleaved Caspase8 (WL00659, Wanleibio, China), PARP and Cleaved PARP (WL01932, Wanleibio, China), Caspase 3 and Cleaved Caspase3 (WL02117, Wanleibio, China), EMT proteins Occludin (TA306787, OriGene Technologies), Vimentin (sc-6260, Santa Cruz), N-cadherin (610921, BD Biosciences) and other primary antibodies HA-tag (#3724, Cell Signaling Technology), Bcl-XL (sc-8392, Santa Cruz), BECN1 (sc-48341, Santa Cruz), FIP200 (PA5-69698, Thermofisher). The  $\beta$ -actin (sc-8432, Santa Cruz) which was kept as an internal control in CaSki/HeLa cells during the course of differentiation with or without the presence of CQ or overexpression of ZBTB28. Moreover, EMT related proteins (N-cad and VIM) were also detected. Equal amounts of protein (40  $\mu$ g) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). Autophagy inhibitor CQ (HY-17589A) and 3MA (HY-19312) were purchased from MedChemExpress.

The membranes, was firstly blocked with PBST (PBS containing 0.1% Tween 20) containing with 5% nonfat dry milk at room temperature for 2 h and then washed with PBST for three times, secondly incubated with the primary antibody at 4 °C overnight and then washed with PBST. After that, membranes were incubated with the corresponding secondary antibody (BL001A, BL003A, Biosharp, China) at room temperature for 45 min and then washed with PBST for another 30 min. Protein bands were visualized by Immobilon Western Chemiluminescent HRP Substrate kit (Millipore Corporation, Billerica, MA, USA), and the band detections were within the linear range.

## ChIP assay

Chromatin immunoprecipitation (ChIP) analysis was performed according to the manual of the SimpleChIP® Enzymatic Chromatin IP Kit (#9003, Cell Signaling Technology). Stably ZBTB28-expressing CaSki/HeLa cells and vector-expressing cells, first were washed with RPMI 1640 medium, then were washed with ice-cold PBS devoid of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  and supplemented with a protease inhibitor cocktail (PIC, P8340, Sigma-Aldrich). Afterwards in order to terminate the reaction, DNA and protein were cross-linked with 1% formaldehyde for 10 min at room temperature followed by 0.125 M glycine for 5 min. Then cells were lysed in lysis buffer (20 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5 mM  $\text{CaCl}_2$ , 1% Triton X-100, PIC) for 10 min and micrococcal nuclease was added for 20 min at 37 °C. In order to acquire 200–900 bp DNA fragments, cells were sonicated on ice of 9 sec pulses at 30% amplitude with an ultrasonic cell disruptor (JY88-IIN, Scientz, China) at an interval of 1 min for five sets. The remanent diluted samples, whose lysates was removed 10  $\mu$ l in advance to serve as an input sample, were incubated with HA-tag antibody (#3274, Cell Signaling Technology) overnight at 4 °C, followed by capture with protein A/G magnetic beads (#9006, Cell Signaling Technology) for 2 h at 4 °C. Rabbit anti-histone H3 antibody (#4620, Cell Signaling Technology) and normal rabbit IgG (#2729, Cell Signaling Technology) were respectively used as positive and negative controls. As recommended, the complexes were precipitated, washed, and eluted. After DNA-protein cross-linkages were incubated with 6  $\mu$ l of 5 M NaCl and 2  $\mu$ l of proteinase K at 65 °C overnight, DNA was washed and purified with Anhydrous ethanol for once, 75% ethanol for 2 times,

then drying at 55 °C for 10 min. 50µl of enzyme free water was added for further using in q-PCR analyses. The primer sequences are shown in Table.S4.

### **Autophagy flux assay**

For the autophagy assay, CaSki and Hela cells were imaged by confocal laser scanning microscope, after transfected with eGFP/eGFP-LC3 for 48 hours.

### **Transmission Electron Microscopy (TEM)**

The cells were stained with uranyl acetate/lead citrate and observed by a Hitachi H-7650 transmission electron microscope (Tokyo, Japan) operated at 100 KV.

### **Luciferase reporter assay**

293T, CaSki and HeLa cells were seeded in 24-well plates and grown to 50-60% confluence. Then the cells were co-transfected with pGL3-gene, HA-ZBTB28, and monitor plasmid pRT-LK (80:1 ratio). After 48 hours, the cells were lysed in 100 µl lysis buffer and the Firefly and Renilla luciferase activities were detected by the Dual-Luciferase Reporter System (Promega) according to the manufacturer's instructions. After the luciferase activity of the tested sample had been normalized, data are represented as the fold induction to that of the corresponding control sample.

### **Spheroid forming assay**

Spheroid culture was performed as previously described [7]. Briefly, 2000 cells were seeded onto 6-well plate, after 2 weeks, the spheroids were examined using microscope (Olympus, Tokyo, Japan). The number of spheroids was calculated using captured images. Spheroid cells larger than 50 µm were considered as formed spheroids. The efficiency of spheroid formation is the percentage of spheroid cells in live cells seeded.

### **Acridine orange (AO)/ethidium bromide (EB) staining**

AO/EB double staining was used to detect apoptosis (A simple technique for quantifying apoptosis in 96-well plates). Briefly, 5000 cells/well were seeded in a 24-well plate. After 24 hours, gently washing with 1× PBS, then the cells were stained with acridine orange (100 µg/ml) and ethidium bromide (100 µg/ml) mixed solutions for 1 min(kit). After staining the cells were washed with 1× PBS, then observed under a microscope (Olympus, Tokyo, Japan) and recorded.

### **EdU (5-ethynyl-2'-deoxyuridine) incorporation assay in vitro**

EdU detection was performed using the BeyoClick™ EdU Cell Proliferation Kit with Alexa Fluor 488 (Beyotime Biotechnology, Haimen, China), according to manufacturer's instructions. In brief, cervical cancer cells were incubated with 10 µM EdU for 2 h at 37 °C. Cells were then fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton X-100 for 15 min at room temperature. Next, the

fixatives were removed, and the cells were washed with PBS containing 3% BSA (4240GR005, BioFroxx). Last, cells were incubated from light in Click Additive Solution for 30 min then stained nucleus with Hoechst. The pictures of EdU detection samples were then acquired under microscope (Olympus, Tokyo, Japan) and photographed. The cell proliferation was further analyzed by counting the ratio of EdU incorporated cells to the total number of cells.

## Immunohistochemistry (IHC)

Briefly, paraffin sections were dewaxed, washed twice in absolute ethanol, follow the instructions (ZSGB-BIO, SP9000) for hydration and antigen retrieval. Next, incubated slides with reagent 1 for 10 min at room temperature to inactivate endogenous peroxidase, and followed by three times washes in PBS for 3 min. Then sections were incubated in blocking solution (Reagent 2) for 15 min, continued by overnight incubation at 4 °C with PCNA (#13110, Cell Signaling Technology), HA-tag antibody in immunohistochemical wet box. Next day, sections were three washes with PBS, then incubated with reagent 3 at 37 °C for 30min in wet box, washed again in PBS, and incubated with reagent 4 at 37 °C for 30min. After three times washed with PBS, immunolabeling was performed with 1x diaminobenzidine (DAB, ZSGB-BIO, ZLI-9018). Finally, the sections were counterstained with hematoxylin (BL702B, Biosharp, China).

## siRNA and transfection

siRNA sequences against human *BECN1* and *FIP200* were purchased from OriGene (OriGene Technologies, Rockville, MD). At a concentration of 10 nM, a pool of three different siRNA duplexes was used to transfections. Transient transfections were performed in 6-well plates using Lipofectamine 2000 (Invitrogen). After transfection 48-72 h, cells were harvested for subsequent assays.

## Statistical analyses

GraphPad Prism 5 was used to conduct the statistical analysis. All data were presented as the mean  $\pm$  standard error of the mean (SEM). Statistical analysis was performed by comparing two groups of data in the way of Student t test. The significance of statistical analysis was clarified by  $*p < 0.05$ ,  $**p < 0.01$  and  $***p < 0.001$ .

# Results

## ZBTB28 is downregulated by CpG methylation in cervical cancer cells and tissues

We have previously shown that the transcription factor ZBTB28 is a tumor suppressor molecule, which is widely expressed in normal tissues and significantly down-regulated in a variety of cancer types [7]. *ZBTB28* expression was silenced in CaSki and HeLa cells, further methylation-specific PCR (MSP) analysis has revealed that the methylation of *ZBTB28* promoter was correlated with its downregulation (Fig.1A). To confirm the role of CpG methylation on the downregulation of *ZBTB28* expression, cervical cancer cells were treated with DNA methylation inhibitor 5-Aza-2-deoxycytidine (5-Aza). As expected, the

expression of *ZBTB28* was restored by 5-Aza accompanied with the reduction of methylation level and increase in unmethylated alleles (Fig.1B). To assess the promoter methylation status, we performed MSP analysis on 48 primary cervical tumors, including 20 paired and 28 tumor tissues. *ZBTB28* methylation was detected in 45/48 (93.75%) tumors but 13/20 (65%) paired adjacent non-tumor tissue samples (Fig.1C), thus indicating that *ZBTB28* methylation is a common event in cervical cancer. Next, we found that *ZBTB28* was downregulated among the The Cancer Genome Atlas (TCGA) cervical cancer database (<https://tcga-data.nci.nih.gov/tcga/>) (Fig.1D). Survival analysis curve calculated from cervical cancer patients from TCGA illustrated that high expression of *ZBTB28* was positively correlated with longer overall survival (Fig.1E).

### **ZBTB28 suppresses the growth and metastasis of cervical cancer cells**

To analyze the functional of ZBTB28 in cervical cancer, we transfected pcDNA3.1(+) framework plasmid or pcDNA-HA-ZBTB28 plasmid into cervical cancer cell lines CaSki and HeLa which lack endogenous *ZBTB28* expression. Ectopic expression of ZBTB28 was confirmed by Reverse transcription (RT)-PCR and Western blot (Fig.2A). CCK8 results showed that exogenous ZBTB28 expression inhibited cell viability of both cell lines (Fig.2B). The inhibitory effect on cell growth was further convinced by colony formation assay, in which ZBTB28 decreased the number and size of colonies in CaSki and HeLa compared with the control cells (Fig.2C). Interestingly, we observed that the cell morphology was changed after re-expression ZBTB28 in CaSki and HeLa cells, presenting a more adhesive contact pattern while the control cells still showed scattered distribution (Fig.2D). Therefore, we hypothesized that ZBTB28 might be involved in tumor cell epithelial mesenchymal transition (EMT).

As we all know, EMT is the key process of metastasis and invasion of cancers [29]. At transcription and post-transcription level, we verified that the epithelial markers E-cadherin and Occludin were up-regulated due to ectopic ZBTB28 while mesenchymal markers N-cadherin and Vimentin were down-regulated in CaSki and HeLa cells (Fig.2E, sFig.2). Furthermore, we conducted Transwell assay to explore the role of ZBTB28 in metastasis of cervix cancer cells. Within expectation, over-expression of ZBTB28 significantly inhibited the ability of migration and invasion of CaSki and HeLa cells compared with control cells (Fig.2F, G). Besides cancer cells metastasis and invasion, EMT also closely related to tumor self-renewal and differentiation [29]. The spheroid formation test proved that ZBTB28 decreased the spheroid formation rate compared to controls, indicating that ZBTB28 affects the self-renewal capacity of single cell and the stemness of cervical tumor cells (Fig.2H). Next, qRT-PCR was used to detect whether ZBTB28 contributed to the regulation of tumor stemness at transcription level. The results illustrated that ZBTB28 downregulated the expression of *NANOG*, *OCT4*, *KLF4*, *ABCG2*, *BMI1*, *MYC*, *TIP30*, *SMAD2*, *STAT3* and *CD44* in cervical cancer cells (Fig.2I). Overall, our study verified that ZBTB28 played an anticancer role through inhibiting the proliferation, growth, migration, invasion and tumorigenicity of cervical cancer cells.

### **ZBTB28 induced cell cycle arrest and apoptosis in cervical cancer cells**

We next explored whether there were other underlying mechanisms about the growth inhibition ability of ZBTB28 in cervical cancer cells. Cell cycle arrest and/or cell apoptosis often related with low cell viability. Hence, flow cytometry analyses were performed to detect cell cycle and apoptosis. The content of DNA was calculated by PI fluorescence intensity, a fluorescent vital dye that can linearly bind to DNA without sequence preference, which can reveal the cell cycle states [30]. PI staining expounded that, in CaSki cells, cell cycle was arrested in S phase by ZBTB28 re-expression accompanied with a decrease in the proportion of G0/G1 phase while the proportion of G2/M phase remained no statistical difference. In the meanwhile, the proportion of G0/G1 phase cells were increased by overexpression of ZBTB28 in HeLa cells, with slight decrease of G2/M phase cells and S phase (there were no statistical difference) (Fig.3A, B). To further confirm that the increase of S phase was resulted from cell cycle arrest induced by ZBTB28 rather than DNA replication, we performed EdU incorporation assay in CaSki cells. The results showed a decrease number of EdU-positive cells and was consistent with our previous hypothesis that ZBTB28 inhibited DNA replication and gave rise to cells arrested in S phase (Fig.3C). Besides, we observed the morphological characteristics of apoptotic cells through transmission electron microscope. The figure 3D revealed that, in ZBTB28 over-expression cells, increased chromatin condensation and formation of apoptotic bodies led to the weakness of intercellular contact and cell integrity. In addition, the AO/EB staining indicated that ZBTB28 induced near 2-fold higher number of apoptotic cells compared with the control cells (Fig.3E). In accordance with AO/EB results, flow cytometry analysis also showed that ZBTB28 increased the proportion of both early and late apoptotic cells (Annexin V+ PI) in CaSki and HeLa (Fig.3F). As a result, ZBTB28 could induce cell cycle arrest and increase cell apoptosis to inhibit cervical cancer growth.

### **ZBTB28 inhibits biological functions of cervical cancer in vivo**

Furthermore, we evaluated whether ZBTB28 could suppress the growth and metastasis of cervical cancer cells *in vivo* using nude mice model (Fig.4A). Without significant differences in mean body weight between the two groups (data not shown), the average volume and weight of tumors in the ZBTB28 group were lower than those in the control group (Fig.4B, C). Then we performed histological analysis (HE, PCNA and TUNEL staining) to further assess the *in vivo* anti-tumor ability of ZBTB28. As indicated by HE staining, the morphological characteristics of ZBTB28 xenografts were more homogeneous than vector xenografts. Compared with higher proliferative index in the control group, the ectopic expression of ZBTB28 inhibits proliferation of cervical cancer xenografts was demonstrated by immunohistochemical staining with a monoclonal antibody against PCNA. At the same time, TdT-mediated dUTP nick end labeling (TUNEL) staining confirmed the conclusion that ZBTB28 promoted the apoptosis of cervical cancer cells (Fig.4D). Furthermore, we established an artificial lung metastasis model, and there is no significant lung metastatic focus was found in the ZBTB28 group (Fig.4E). All the results indicated that ZBTB28 can act as a tumor suppressor to inhibit subcutaneous tumor growth and pulmonary metastatic foci formation *in vivo*.

### **ZBTB28 induced autophagy in cervical cancer cells**

In our research, electron microscopic photograph showed that ZBTB28 induced the formation of double-membrane structures (the autophagosome) in cervical cancer cells (Fig.5A). Thus, we examined whether ZBTB28 could induce autophagy in cervical cancer. During the autophagy, MAP1LC3B/LC3B, which is scattered distributed in non-autophagy cells, experienced processing and amalgamated into puncta in cytoplasm [31]. By transient transfecting GFP-LC3B plasmid, we assessed the formation of GFP-LC3B puncta in ZBTB28 over-expression cervical cancer cells. Indeed, ZBTB28 increased the formation of LC3B puncta (Fig.5B). This phenomenon implied that ZBTB28 enriched the formation of autophagosome in CaSki and HeLa cells. Even though the number of puncta LC3B in each cell is considered as an accurate indicator of the quantity of autophagosome, the accumulation of autophagosomes does not always represent the induction of autophagy [32]. Thus, the measurement of autophagic flux is essential to confirm that ZBTB28 induces autophagy rather than autophagosome mature hindrance. It's generally accepted that the conversion of LC3I to LC3II concomitant with the consumption of SQSTM1/p62 is a hallmark of the increasing of autophagy [33]. Interestingly, we found that LC3I was converted to LC3II and p62 was reduced after the over-expression of ZBTB28 in cervical cancer cells. To further confirm the changes of LC3 and p62 were resulted from the increase of autophagy flux, we used autophagy inhibitors chloroquine(CQ) and 3-methyladenine(3MA) to block autophagy at different stages in the turnover assay [32]. Treatment of CQ overcame the reduction of p62 induced by ZBTB28 compared with control cells. However, CQ which works by blocking autophagosome-lysosome fusion in the later stage of autophagy had no significant effect on LC3 turnover (Fig.5C) [34]. Thus, we used 3MA, an early-stage autophagy inhibitor inhibiting autophagosome membrane formation, to reconfirm the effect of ZBTB28-induced autophagy [35]. As expected, ZBTB28 induced the degradation of p62 and the conversion of LC3I to LC3-II was restricted by 3MA (Fig.5D). Collectively, the data clearly indicated that the pro-autophagic effect was exerted by the over-expression of ZBTB28 in cervical cancer cells.

### **Autophagy is involved in ZBTB28-induced cell apoptosis**

Several researches have suggested that activation of apoptosis is a common event in cancer cells in response to autophagy induction [21, 23, 25]. Based on these findings, we investigated whether there were causal links between ZBTB28-induced autophagy and apoptosis. Firstly, we chose autophagy inhibitor CQ and 3MA to block ZBTB28-induced autophagy and then examined the apoptotic effect of ZBTB28 on CaSki and HeLa cells. As expected, treatment with CQ or 3MA prevented the increase of cleaved-caspase 8, cleaved-caspase 3 and cleaved-PARP caused by ZBTB28 (Fig.5E, F). Hence, we hypothesized that ZBTB28-induced cell apoptosis might relate to the activation of autophagy. In order to provide more evidences for the specific implication of autophagy in ZBTB28-induced apoptosis, we used siRNA targeting *BECN1* to disturb the nucleation of autophagosomes. Knockdown of *BECN1* reduced ZBTB28-induced autophagy which was characterized as the inhibition of LC3 conversion and the reduction of p62 degradation. Meanwhile, downregulation of *BECN1* decreased the cleavage fragment of caspase 8, caspase 3 and PARP in ZBTB28 overexpression cells (Fig.5G). Moreover, ZBTB28-induced growth inhibition was reversed after abrogation of autophagy by silencing *BECN1*, and the treatment of CQ at the concentration that has no influence on cell viability attenuated the death of cervical cancer cells induced by ZBTB28 (Fig.5H). In a word, all the data indicates that there might exist an intrinsic relationship

between autophagy and apoptosis induced by ZBTB28 which needs further explore the underlying molecular mechanism.

### **ZBTB28 mediated autophagy through degradation of Bcl-XL and reduction of the Bcl-XL–BECN1 complex**

It had been reported that the autophagy of HeLa cells was dependent on BECN1 [36]. However, our results showed that over-expression of ZBTB28 had little effect on the expression of *BECN1*, and *siBECN1* could disturb nucleation of autophagosomes (Fig.5G, sFig.3A). This phenomenon attracted us to analysis the potentially mechanisms underlying it. It is well-documented that Bcl-2 family proteins (BCL2, Bcl-XL and MCL1) can regulate autophagy by displacing BECN1 from the BECN1-Vps34 complex [20]. Thus qRT-PCR were performed to verify whether ZBTB28 could regulate BCL-2 family genes. The results revealed that ZBTB28 downregulated the expression of *Bcl-XL* in both CaSki and HeLa cells while there was no clear difference between *BCL2* and *MCL1* (Fig.6A, sFig.3B, C). Further, we used online database (<http://jaspar.genereg.net/>) to find four predicted ZBTB28 transcription factor-binding sites (TFBSs, from + 47 to + 60, + 50 to + 63, + 723 to + 736 and + 942 to + 955) in *Bcl-XL* promoter region (Fig.6B). Moreover, the ChIP assay with chromatin isolated from Hela cells and antibodies against HA-ZBTB28 confirmed that ZBTB28 was enriched at the predicted region of *Bcl-XL* promoter, while a control IgG antibody showed no significant enrichment over the entire surveyed region (Fig.6C). Then the promoter region of *Bcl-XL* containing different predicted TFBSs of ZBTB28 were cloned into the pGL3-Basic reporter vector, respectively. After mutation of the predicted site, the corresponding *Bcl-XL* mutant reporter plasmid was constructed. Luciferase reporter assay showed that ZBTB28 down-regulated promoter activity of *Bcl-XL* wild-type #1 but has no effect on wild-type #2 or mutant of *Bcl-XL*. (Fig.6D, sFig.3D). These results revealed that ZBTB28 reduced the expression of *Bcl-XL* by inhibiting its promoter activity.

Because the dissociation of Bcl-XL-BECN1 complex can trigger autophagy, we examined whether the ZBTB28-induced reduction of Bcl-XL could break the complex containing Bcl-XL and BECN1 by immunoprecipitation. The interaction between endogenous BECN1 and Bcl-XL was detected using antibody against BECN1. Notably, as shown in Figure 6E, we verified that BECN1 was constitutively bound to Bcl-XL and downregulated by ZBTB28. Further restoration of Bcl-XL cancelled the decrease of BECN1–Bcl-XL complex induced by ZBTB28 (Fig.6E). Taken together, these results suggested that ZBTB28 activated autophagy by alleviating the suppression of Bcl-XL on BECN1.

### **Upregulation of FIP200 promotes ZBTB28-induced autophagy to mediate cell apoptosis**

Our present results showed that both pharmacological inhibitors of autophagy and genetic knockdown of *BECN1* could inhibit apoptosis and concomitant with caspase inactivation. This indicated that ZBTB28-induced autophagy might trigger the apoptotic cascade. Therefore, we investigated whether ZBTB28 could interact with autophagy-related genes (*ATGs*) at transcription level with a direct effect on inducing autophagy. It was worth noticing that ZBTB28 up-regulated the expression level of endogenous *FIP200* and *ATG16L2* in both CaSki and HeLa cells while there were no significant impacts on other *ATGs* (Fig.7A, sFig.4A, B). Likewise, the open-access database JASPAR was used to search potential ZBTB28 TFBSs on *FIP200* and *ATG16L2* promoter. Two putative binding sites on *FIP200* promoter (positions: - 108 to - 95

and + 494 to + 507) and three sites on *ATG16L2* promoter (positions: - 991 to - 978, - 934 to - 921 and - 541 to - 533) were obtained from the database (Fig.7B, sFig.4C). We then conducted the ChIP assay to confirm these binding sites. ZBTB28-binding consensus sequence in *FIP200* or *ATG16L2* promoter region was examined with HA-tag antibody, followed by qPCR assay with primers that were designed close to the predicted site. The results showed that exogenous ZBTB28 expression was enriched in the predicted region compared to IgG (Fig.7C, sFig.4D). To further prove this result, we employed the luciferase reporter assay to monitor *FIP200* and *ATG16L2* promoter activity which was regulated by ZBTB28 in living cells. Consistent with our hypothesis, ZBTB28 can directly activate the *FIP200* and *ATG16L2* wild-type promoter activities in 293T and cervical cancer cells and was incapable of activating the promoters of mutant one (Fig.7D, E, sFig.4E). It is well known that FIP200 is an indispensable component of the ULK1 complex which plays a key role in the initiation of autophagy [37]. But the role of ATG16L2 in autophagy is still controversial [38, 39]. Hence, in our research, siRNAs targeting *FIP200* were used to block autophagy to check the causal link between ZBTB28-induced autophagy and apoptosis. The results showed that the knockdown of FIP200 decreased the conversion of LC3-I to LC3-II and the degradation of p62 (Fig.7F), which indicated the jamming of an autophagy response. More surprisingly, knockdown of FIP200 attenuated ZBTB28-induced apoptosis, manifested as the decrease in cleaved fragments of caspase8, caspase 3 and PARP (Fig.7F). In addition, the deletion of FIP200 eliminated the growth inhibition of cervical cancer cells induced by ZBTB28 (Fig.7G). Collectively, the above results posited that ZBTB28-induced apoptosis was highly relied on FIP200-induced autophagy, and involved with the activation of caspases.

### **ZBTB28 increased the sensitivity to Paclitaxel, Cisplatin and 5-fluorouracil of cervical cancer cells**

As shown in previous results, ectopic expression of ZBTB28 induced S-phase or G0/G1-phase cell cycle arrest in cervical cancer cells. Cell cycle status can affect sensitivity of tumor cells to chemotherapeutic drugs such as Paclitaxel, Cisplatin and 5-FU. Given the combination of Paclitaxel, platinum drugs, 5-FU and radiotherapy is a safe and tolerable treatment for persistent or recurrent cervical carcinoma [40], we wondered whether ZBTB28 could influence the chemo-sensitivity of cervical tumor cells. IC50 assay was performed to detect the effect of ZBTB28 over-expression on cells sensitivity toward those agents. Noteworthy, the results showed an increased inhibition rate of those drugs on ZBTB28 over-expression CaSki and HeLa cell lines with a decreased IC50 of those medications (Fig.8A-C). Specifically, ectopic expression of ZBTB28 could reduce the IC50 of 5-Fu from 33.5 to 8.8( $\mu$ M) and 103.7 to 9.1( $\mu$ M), the IC50 of Cisplatin from 23.4 to 3.5( $\mu$ M) and 49.3 to 7.1( $\mu$ M) as well as that of Paclitaxel from 0.12 to 0.0013( $\mu$ M) and 0.13 to 6E-61( $\mu$ M) in CaSki and HeLa cell lines, respectively (Fig.8C). Therefore, our results showed ZBTB28 can sensitize cervical cancer cells to chemotherapy reagents Paclitaxel, Cisplatin and 5-Fu. These results opened up a new insight of the synergistic role of ZBTB28 in the chemotherapy of cervical cancer. In conclusion, ZBTB28 may be used as a potential therapeutic target in cervical cancer treatment.

## **Discussion**

Although the formation of autophagosome often referred as the survival mechanism of tumor cells under stress conditions, it can also contribute to cell death demonstrated by lots of related researches [41, 42]. In the present study, we focused on the function of transcription factor ZBTB28 on cervical cancer and the links between autophagy and cervical cancer cells apoptosis. We found that ZBTB28 could inhibit malignant ability of cervical cancer cells *in vivo* and *in vitro*, and autophagy-related apoptosis was involved in this process (Fig.S1).

For cervical cancer patients who were diagnosed early, receiving timely treatment the 5-year survival are over 90% [43]. However, the survival rate will drop sharply if the tumor has invaded the surrounding tissues or metastasized to other organs. Therefore, developing new biomarker for early diagnosis of cervical cancer and finding a more effective way to improve the life quality of patient is an urgent need. We have proved that DNA methylation-based silencing of *ZBTB28* is functionally participated in the occurrence of cervical cancer. It was reported that, even after HPV clearance, the silencing of TSGs caused by DNA hypermethylation would still trigger the carcinogenesis of cervix [44]. In our study, the methylation rate of *ZBTB28* in tumor tissues was over 90%, which is equivalent to the detection rate of *hrHPV* DNA in them (Table.S1). This suggests that there may be a possibility that the methylation status of *ZBTB28* will become a valuable marker for cervical cancer screening.

It is worth noticing that, there is no available targeted medicine approved by U.S. Food and Drug Administration for cervical cancer except for bevacizumab currently [45]. Moreover, cytotoxic effects or drug tolerance are obvious issues in the existing chemotherapy regents in clinical practice. In order to improve this essential problem, we need to explore a new therapeutic target for advanced cervical cancer patients [46]. Our drug sensitivity assays revealed that ZBTB28 can increase the sensitivity of cervical cancer cells to current chemo-reagents Cisplatin, Paclitaxel and 5-FU [47, 48]. This suggests that ZBTB28 may be enhancing the current chemotherapy, and may become a potential therapeutic target to guide treatment decisions for cervical cancer.

Here, we found that autophagy was enhanced by re-expression of ZBTB28 in cervical cancer cells. Autophagy is a precise regulated procedure that can induce the formation of double-membrane vacuoles (autophagosome) and package unnecessary or damaged organelles thereafter deliver them to lysosomes for elimination [8, 49]. We used autophagy inhibitors, such as CQ and 3MA, to act as blockade to prevent ZBTB28-induced autophagy. Meanwhile, we found that autophagy inhibitors attenuate the pro-apoptotic effect of ZBTB28 on cervical cancer cells. In order to exclude the possible influence of the inhibitors on cells, we knocked down BECN1 to disturb the generation of autophagosome. Consistent with the previous results, silencing of BECN1 blocked autophagy and apoptosis caused by ZBTB28 simultaneously. Nevertheless, we found that BCEN1 took part in the process of autophagy which couldn't be regulated by ZBTB28 directly.

As a BH3-only protein, BECN1 interacts with Bcl-2 family (in particular Bcl-2, Bcl-XL and MCL1) by virtue of its BH3 domain [50]. The relative amount of BCL2 family-BECN1 complex in cells can bear on autophagy [20]. However, we were incapable to detect whether ZBTB28 affected the status of *BCL2* and

*MCL1*. Alternatively, we found that the degradation of Bcl-XL was a direct consequence of transcriptional and post-transcriptional regulation of ZBTB28. ZBTB28 stimulated autophagy by dissociating the interaction between BECN1 and Bcl-XL. Liberated BECN1 from its inhibition by Bcl-XL gave rise to constitution of autophagosome. Consequently, ZBTB28 impaired the Bcl-XL-BECN1 complex instead of increasing BECN1 to enhance autophagy.

Different *ATGs* regulate different stages of autophagy, and their expression level and intricacies of molecular regulation determine the direction of autophagy [49]. Conventional autophagy initiation of autophagosomes formation usually requires two key parts. One is regulated by the BECN1-Vps34 (class III PI3K) complex that responded to cellular stresses [51]. Secondly, the formation of autophagosomes is dependent on the FIP200-ULK1/2-ATG13-ATG101 complex which is the upstream regulator of the autophagy pathway sensitive to the cell metabolic status [31]. We have been screened out FIP200 as a possible target for ZBTB28 via examining the expression of *ATGs* family. Silencing FIP200 successfully reversed the autophagy induced by ZBTB28 and reduced the apoptosis as well as activation of caspase cascade. Existing studies have shown that the expansion of autophagosomal membranes is fundamental for the caspase-8 self-activation [52]. During the process of autophagosome formation, the association of LC3-II and p62 attracts ATG5-ATG16L-ATG12 complex to the autophagosomal membranes. Atg5 on LC3- and Atg16L-positive autophagosomal membranes subsequently associates with Fas-associated death domain protein (FADD), an adaptor protein for caspase-8 activation, recruits caspase-8 to autophagosomal membranes then facilitates the development of intracellular death-inducing signaling complex (iDISC). iDISC formation activated endogenous caspase-8 to initiate the caspase-8 cascade, leading to autophagy-related apoptosis [52]. Beyond that, autophagosomes-lysosomes fusion was involved in the maturation of CTSD (cathepsin D). CTSD exists in autolysosome which is formed by the fusion of autophagosomes with lysosomes and is released to the aqueous component of the cytoplasm by lysosomal membrane permeabilization. M-CTSD which transported into the nucleus triggers caspase 3 cleavage and apoptosis [53]. More in-depth understanding of the molecular mechanism of ZBTB28 induced autophagy-related apoptosis will provide a new theoretical evidence for an intracellular machinery of autophagy and cell death.

## Conclusion

Our research suggests that the decrease in autophagy activation is correlated with the silence of *ZBTB28* by promoter methylation. the enhancing autophagic activity may become a new strategy to inhibit the progression of cervical cancer. In addition, the combination of demethylation drugs or autophagy agonists with chemotherapeutic reagents may enhance chemotherapy-induced cervical cancer cell death. In conclusion, ZBTB28 may have utility in the clinical domain as it can be a specificity biomarker for screening and diagnosis or as a target of epigenetic therapies in cervical cancer.

## Abbreviations

3MA: 3-methyladenine; 5-FU: 5-fluorouracil; 5-Aza: 5-aza-2'-deoxycytidine; AO/EB: acridine orange/ethidium bromide; ATGs: autophagy-related genes; ATG5: autophagy gene 5; BECN1: Beclin1; ChIP: chromatin immunoprecipitation; CQ: chloroquine; EdU: 5-ethynyl-2'-deoxyuridine; EMT: epithelial mesenchymal transition; FIP200: FAK Family Kinase-Interacting Protein Of 200 KDa; IC50: half maximal inhibitory concentration; LC3-I: the nonlipidated form of LC3B; LC3-II: the lipidated form of LC3B; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; MSP: methylation-specific PCR; p62: SQSTM1/p62; ZBTB28: Zinc-finger and BTB/POZ (Poxvirus and Zinc-finger) domain-containing family protein 28.

## **Declarations**

### **Ethics approval and consent to participate**

The study was authorized by the Institutional Ethics Committees of The First Affiliated Hospital of Chongqing Medical University and conformed to the principles of the Declaration of Helsinki.

### **Consent for publication**

We have obtained consent to publish from the participant to report individual patient data.

### **Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### **Competing Interests**

No potential conflicts of interest were disclosed.

### **Funding**

This study was supported by National Natural Science Foundation of China (#81372238, 81572769) and Natural Science Foundation of Chongqing (2020ZY013799, cstc2020jcyj-bshX0026)

### **Authors' Contributions**

T.X. conception and design. L.L., Y.G., K.X. performed majority of experiments. W.C., J.X., Q.X. performed experiments and analyzed data. Z.C., R.Y., J.T. collected samples. L.L., Y.G. drafted the manuscript. L.L., J.M., X.L. reviewed data and manuscript. TX, L.L., Y.G., W.P. reviewed data and finalized the manuscript. All authors reviewed and approved the final version.

### **Acknowledgments**

The authors thank Prof. Qian Tao (the Chinese University of Hong Kong, Hong Kong, China) for generously providing primers and plasmids.

## References


1. Ward ZJ, Grover S, Scott AM, Woo S, Salama DH, Jones EC, El-Diasty T, Pieters BR, Trimble EL, Vargas HA et al: The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis. *Lancet Oncol.* 2020;21:1089-1098.
2. Cancer Genome Atlas Research N, Albert Einstein College of M, Analytical Biological S, Barretos Cancer H, Baylor College of M, Beckman Research Institute of City of H, Buck Institute for Research on A, Canada's Michael Smith Genome Sciences C, Harvard Medical S, Helen FGCC et al: Integrated genomic and molecular characterization of cervical cancer. *Nature.* 2017;543:378-384.
3. Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA, Jelovac D et al: A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). *Ann Oncol.* 2017;28:505-511.
4. Xu L, Li X, Chu ES, Zhao G, Go MY, Tao Q, Jin H, Zeng Z, Sung JJ, Yu J: Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. *Gut.* 2012;61:977-985.
5. Okabe S, Fukuda T, Ishibashi K, Kojima S, Okada S, Hatano M, Ebara M, Saisho H, Tokuhisa T: BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor. *Mol Cell Biol.* 1998;18:4235-4244.
6. Yang Q, Gao J, Xu L, Zeng Z, Sung JJ, Yu J: Promoter hypermethylation of BCL6B gene is a potential plasma DNA biomarker for gastric cancer. *Biomarkers.* 2013;18:721-725.
7. Xiang T, Tang J, Li L, Peng W, Du Z, Wang X, Li Q, Xu H, Xiong L, Xu C et al: Tumor suppressive BTB/POZ zinc-finger protein ZBTB28 inhibits oncogenic BCL6/ZBTB27 signaling to maintain p53 transcription in multiple carcinogenesis. *Theranostics.* 2019;9:8182-8195.
8. Macintosh RL, Ryan KM: Autophagy in tumour cell death. *Semin Cancer Biol.* 2013;23:344-351.
9. Klionsky DJ, Emr SD: Autophagy as a regulated pathway of cellular degradation. *Science.* 2000;290:1717-1721.
10. Yang Y, Klionsky DJ: Autophagy and disease: unanswered questions. *Cell Death Differ.* 2020;27:858-871.
11. Mizushima N, Levine B: Autophagy in Human Diseases. *N Engl J Med.* 2020;383:1564-1576.
12. Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, Baehrecke EH, Lenardo MJ: Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. *Science.* 2004;304:1500-1502.
13. Jin H, Ma J, Xu J, Li H, Chang Y, Zang N, Tian Z, Wang X, Zhao N, Liu L et al: Oncogenic role of MIR516A in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy. *Autophagy.* 2020;1-15.
14. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU: Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. *Nat Cell Biol.* 2006;8:1124-1132.

15. Grishchuk Y, Ginet V, Truttmann AC, Clarke PG, Puyal J: Beclin 1-independent autophagy contributes to apoptosis in cortical neurons. *Autophagy*. 2011;7:1115-1131.
16. Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y, Shimizu S: Discovery of Atg5/Atg7-independent alternative macroautophagy. *Nature*. 2009;461:654-658.
17. Hara T, Mizushima N: Role of ULK-FIP200 complex in mammalian autophagy: FIP200, a counterpart of yeast Atg17? *Autophagy* 2009, 5(1):85-87.
18. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G: Self-eating and self-killing: crosstalk between autophagy and apoptosis. *Nat Rev Mol Cell Biol*. 2007;8:741-752.
19. Eisenberg-Lerner A, Kimchi A: The paradox of autophagy and its implication in cancer etiology and therapy. *Apoptosis*. 2009;14:376-391.
20. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B: Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. *Cell*. 2005;122:927-939.
21. Zhang P, Zheng Z, Ling L, Yang X, Zhang N, Wang X, Hu M, Xia Y, Ma Y, Yang H et al: w09, a novel autophagy enhancer, induces autophagy-dependent cell apoptosis via activation of the EGFR-mediated RAS-RAF1-MAP2K-MAPK1/3 pathway. *Autophagy*. 2017;13:1093-1112.
22. Chen S, Yuan J, Yao S, Jin Y, Chen G, Tian W, Xi J, Xu Z, Weng D, Chen J: Lipopolysaccharides may aggravate apoptosis through accumulation of autophagosomes in alveolar macrophages of human silicosis. *Autophagy*. 2015;11:2346-2357.
23. Ginet V, Puyal J, Rummel C, Aubry D, Breton C, Cloux AJ, Majjigapu SR, Sordat B, Vogel P, Bruzzone S et al: A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis. *Autophagy*. 2014;10:603-617.
24. Sun D, Tao W, Zhang F, Shen W, Tan J, Li L, Meng Q, Chen Y, Yang Y, Cheng H: Trifolirhizin induces autophagy-dependent apoptosis in colon cancer via AMPK/mTOR signaling. *Signal Transduct Target Ther*. 2020;5:174.
25. Zhang L, Fu L, Zhang S, Zhang J, Zhao Y, Zheng Y, He G, Yang S, Ouyang L, Liu B: Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. *Chem Sci*. 2017;8:2687-2701.
26. Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT et al: Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. *Blood*. 2010;116:3227-3237.
27. Kong X, Chen J, Xie W, Brown SM, Cai Y, Wu K, Fan D, Nie Y, Yegnasubramanian S, Tiedemann RL et al: Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties. *Cancer Cell*. 2019;35:633-648.e637.
28. Qadeer ZA, Valle-Garcia D, Hasson D, Sun Z, Cook A, Nguyen C, Soriano A, Ma A, Griffiths LM, Zeineldin M et al: ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. *Cancer Cell*. 2019;36:512-527 e519.

29. Lu W, Kang Y: Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. *Dev Cell*. 2019;49:361-374.
30. Kalejta RF, Shenk T, Beavis AJ: Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry. *Cytometry*. 1997;29:286-291.
31. Yang Z, Klionsky DJ: Mammalian autophagy: core molecular machinery and signaling regulation. *Curr Opin Cell Biol* 2010, 22(2):124-131.
32. Mizushima N, Yoshimori T, Levine B: Methods in mammalian autophagy research. *Cell*. 2010;140:313-326.
33. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B, Sadoshima J: Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. *Circ Res*. 2007;100:914-922.
34. Chen T, Cen D, Ren Z, Wang Y, Cai X, Huang J, Di Silvio L, Li X, Han G: Bismuth embedded silica nanoparticles loaded with autophagy suppressant to promote photothermal therapy. *Biomaterials*. 2019;221:119419.
35. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P, Shen HM: Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. *J Biol Chem*. 2010;285:10850-10861.
36. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B: JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. *Mol Cell*. 2008;30:678-688.
37. Hara T, Takamura A, Kishi C, Iemura S, Natsume T, Guan JL, Mizushima N: FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. *J Cell Biol*. 2008;181:497-510.
38. Khor B, Conway KL, Omar AS, Biton M, Haber AL, Rogel N, Baxt LA, Begun J, Kuballa P, Gagnon JD et al: Distinct Tissue-Specific Roles for the Disease-Associated Autophagy Genes ATG16L2 and ATG16L1. *J Immunol*. 2019;203:1820-1829.
39. Ishibashi K, Fujita N, Kanno E, Omori H, Yoshimori T, Itoh T, Fukuda M: Atg16L2, a novel isoform of mammalian Atg16L that is not essential for canonical autophagy despite forming an Atg12-5-16L2 complex. *Autophagy*. 2011;7:1500-1513.
40. Maneo A, Landoni F, Cormio G, Colombo A, Placa F, Pellegrino A, Mangioni C: Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma. *Ann Oncol*. 1999;10:803-807.
41. Gump JM, Thorburn A: Autophagy and apoptosis: what is the connection? *Trends Cell Biol*. 2011;21:387-392.
42. Mizushima N, Levine B, Cuervo AM, Klionsky DJ: Autophagy fights disease through cellular self-digestion. *Nature*. 2008;451:1069-1075.
43. Xu W, Xu M, Wang L, Zhou W, Xiang R, Shi Y, Zhang Y, Piao Y: Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers. *Signal Transduct Target Ther*. 2019;4:55.

44. Rogeri CD, Silveira HCS, Causin RL, Villa LL, Stein MD, de Carvalho AC, Arantes L, Scapulatempo-Neto C, Possati-Resende JC, Antoniazzi M et al: Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer. *Gynecol Oncol.* 2018;150:545-551.
45. Tewari KS, Sill MW, Long HJ, 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM et al: Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med.* 2014;370:734-743.
46. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 2009;27:4649-4655.
47. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF et al: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol.* 2004;22:3113-3119.
48. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T et al: Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. *J Clin Oncol.* 2015;33:2129-2135.
49. Allen EA, Baehrecke EH: Autophagy in animal development. *Cell Death Differ.* 2020;27:903-918.
50. Oberstein A, Jeffrey PD, Shi Y: Crystal structure of the Bcl-XL-Becn1 peptide complex: Becn1 is a novel BH3-only protein. *J Biol Chem.* 2007; 282:13123-13132.
51. Kang R, Zeh HJ, Lotze MT, Tang D: The Becn1 network regulates autophagy and apoptosis. *Cell Death Differ.* 2011;18:571-580.
52. Young MM, Takahashi Y, Khan O, Park S, Hori T, Yun J, Sharma AK, Amin S, Hu CD, Zhang J et al: Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. *J Biol Chem.* 2012;287:12455-12468.
53. Di YQ, Han XL, Kang XL, Wang D, Chen CH, Wang JX, Zhao XF: Autophagy triggers CTSD (cathepsin D) maturation and localization inside cells to promote apoptosis. *Autophagy.* 2020;1-23.

## Figures



**Figure 1**

Expression and methylation of ZBTB28 in cervical cancer. (A) ZBTB28 expression and methylation status in cervical cancer cell lines. H1299 was used as a positive control, and ddH<sub>2</sub>O was used as a negative control. (B) Impact of the 5-Aza treatments on ZBTB28 expression and methylation status in cervical cancer cell lines. Demethylation was measured by qMSP. (C) ZBTB28 methylation in primary cervical cancer tissues (n=48) and adjacent non-cancerous tissues (n=20) was measured by MSP. Only

representational gel images were shown for illustration. (D) ZBTB28 expression in cervical cancer and adjacent normal tissues from TCGA. (E) Analyses of the association between ZBTB28 expression and survival in cervical cancer patients. Data were obtained from the TCGA. M, methylated; U, unmethylated. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .




Figure 2

Tumor suppressive functions of ZBTB28 in cervical cancer cells. (A) RT-PCR and western blot analysis confirmed the exogenous expression of ZBTB28 in CaSki and HeLa cells, with  $\beta$ -actin as a control. (B) Ectopic ZBTB28 expression impacts cervical cancer cell growth were analyzed by the CCK-8 kit. (C) Re-expression of ZBTB28 suppressed colony formation in CaSki and HeLa cells. (D) Morphological changes of cervical cancer cells that stable transfected with pcDNA-3.1 or pcDNA-ZBTB28 by using phase contrast microscopy. (E) EMT marker were detected by RT-PCR and western blot assay. (F, G) Pictures were taken at 48 h after seeding, the relative ratio of migration and invasion cells per field was shown. (H) Representative spheroid-forming cells images were taken at 14 days after seeding. (I) Overexpression of ZBTB28 in cervical cancer cells downregulated the mRNA expression level of stemness-related genes. All statistical data were shown as mean  $\pm$  SEM. Scale bar: 200  $\mu$ m; \* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001.




Figure 3

ZBTB28 induced cell cycle arrest and promoted cell apoptosis. (A, B) Flow cytometry analysis of cell cycle of CaSki and HeLa cells which was overexpression pcDNA 3.1 or pcDNA-ZBTB28 by PI staining. (C) EdU incorporation in the growing CaSki cells that with/without pcDNA-ZBTB28 were analyzed. (D) Transmission electron micrograph of apoptotic cells: the proportion of apoptotic bodies were increased in ZBTB28-transfected CaSki and HeLa cells, relative to the pcDNA 3.1-transfected control cells (CaSki: 4000x, Scale bar: 5  $\mu$ m; HeLa: 6000x, Scale bar: 2  $\mu$ m). (E) Ectopically expressed ZBTB28 induced apoptosis in cervical cancer cells were tested by AO/EB staining assay. (F) Flow cytometry analysis of apoptotic cell population by Annexin V/PI staining. All statistical data were shown as mean  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .





Figure 4

ZBTB28 suppressed tumorigenicity in vivo. (A) Representative pictures showing tumor growth 18 days after subcutaneously implanted cervical cancer cells. (B) Tumors' volume was measured on day 4, 8, 10, 12, 14, 16, 18. (C) The weight of vector-group and ZBTB28-group tumors were measured respectively (n=5). (D) Representative images of HE staining, PCNA expression. Apoptosis was assessed by TUNEL assays in xenografts. (E) HeLa cells were intravenously injected into BALB/c mice to induce lung

metastasis. Lung metastatic loci were counted on day 15. All statistical data were shown as mean  $\pm$  SEM. \* $p < 0.05$ .



**Figure 5**

Blocking ZBTB28-induced autophagy attenuated apoptosis in cervical cancer cells. (A) The data were shown as representative TEM images of cervical cancer cells which transfected with pcDNA-3.1 or pcDNA-ZBTB28. Arrows pointed the characteristic of autophagosomes. (20000x, Scale bar: 1  $\mu$ m). (B)

Stable transfected cells were transiently transfected with EGFP or EGFP-LC3B. Photographs were taken under a confocal microscopy. (C, D) Stable transfected cells were treated with CQ (20  $\mu$ M) or 3MA (10 mM) for 24 hours. p62, LC3 were detected by western blot.  $\beta$ -actin was used as negative control. (E, F) Stable transfected cells were treated with CQ (20  $\mu$ M) or 3MA (10 mM) for 24 hours. Casp8, Casp3, and PARP were detected by western blot.  $\beta$ -actin was used as negative control. (G) 48 hours after transfection with siBECN1 or control siRNA, the expression of BECN1, p62, LC3, Cleaved-casp8, Casp3, Cleaved-casp3 and Cleaved-PARP were evaluated by western blot.  $\beta$ -actin was used as negative control. (H) Stable transfected CaSki and HeLa cells were treated with CQ (1  $\mu$ M) or re-transfected with siBECN1 and control siRNA. 72 hours after treatment, cell viability was assessed by CCK8 assay. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

Image not available with this version

## Figure 6

Bcl-XL plays a key role in ZBTB28-induced autophagy. (A) Expression of Bcl-XL in stable transfected cervical cancer cells. (B) Structure of wild-type and mutant Bcl-XL reporter plasmid. (C) % input of Bcl-XL DNA by HA-tag antibody were tested by CHIP-PCR. Then products of CHIP-PCR were used for electrophoresis. (D) Promoter luciferase activity of wild-type and mutant Bcl-XL in cervical cancer cells. (E) CaSki and HeLa cells were transfected with Bcl-XL. 60 hours after transfection, the indicated proteins were detected by western blot after co-immunoprecipitation with BECN1 antibody. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .





Figure 7

ZBTB28 upregulated FIP200 to induce autophagy and apoptosis. (A) qRT-PCR results of FIP200 mRNA expression in stable transfected cervical cancer cells. (B) Structure of wild-type and mutant FIP200 reporter plasmid. (C) % Input of FIP200 DNA by HA-tag antibody were tested by ChIP-PCR. Then products of ChIP-PCR were used for electrophoresis. (D) The effect of ZBTB28 on FIP200 promoter activity was detected by dual luciferase reporter system. (E) CaSki and HeLa cells were transfected with pcDNA3.1 or

ZBTB28, then tested promoter luciferase activity of mutant FIP200 in live cells. (F) 48 hours after transfection with siFIP200 or control siRNA, the expression of FIP200, p62, LC3, Cleaved-casp8, Casp3, Cleaved-casp3 and Cleaved-PARP were evaluated by western blot.  $\beta$ -actin was used as negative control. (G) Stable transfected CaSki and HeLa cells were re-transfected with siFIP200 or control siRNA. 72 hours after transfection, cell viability was assessed by CCK8 assay. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .



**Figure 8**

ZBTB28 sensitized the respond of cervical cancer cells to 5-FU, Cisplatin and Paclitaxel. (A, B) Inhibition rate of proliferation in pcDNA3.1 or ZBTB28 transfected cells treated with gradient concentration of 5-FU,

Cisplatin and Paclitaxel. (C) IC50 values of 5-FU, Cisplatin and Paclitaxel for cervical cancer cells. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementalfigures.pdf](#)
- [supplementaltables.pdf](#)